Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Quarterly results
Inv. presentation
Acq. announced
CC transcript

MADRIGAL PHARMACEUTICALS, INC. (MDGL) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/02/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Underwriting Agreement",
"FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Number of Shares: [ ] Warrant No. Original Issue Date: [ ], 2023 MADRIGAL PHARMACEUTICALS, INC.",
"Hogan Lovells US LLP"
08/08/2023 8-K Quarterly results
Docs: "Madrigal Pharmaceuticals Provides Corporate Updates and Reports Second Quarter 2023 Financial Results"
07/17/2023 8-K Quarterly results
06/30/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Madrigal Pharmaceuticals Announces Rolling Submission of New Drug Application to U.S. FDA Seeking Accelerated Approval of Resmetirom for the Treatment of NASH with Liver Fibrosis"
05/09/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Amendment No. 1 to Sales Agreement, by and between Madrigal Pharmaceuticals, Inc. and Cowen and Company, LLC",
"Legal Opinion of Hogan Lovells US LLP"
05/09/2023 8-K Quarterly results
Docs: "Madrigal Pharmaceuticals Provides Corporate Updates and Reports First Quarter 2023 Financial Results"
02/23/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Madrigal Pharmaceuticals Provides Corporate Updates and Reports 2022 Fourth Quarter and Full Year Financial Results"
02/09/2023 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Form of Tranche 2 Warrant Agreement, by and among Madrigal Pharmaceuticals, Inc. and Hercules Capital, Inc. and affiliates",
"Loan and Security Agreement, as amended by the First Amendment to Loan and Security Agreement, by and among Madrigal Pharmaceuticals, Inc., Canticle Pharmaceuticals, Inc., the several banks and other financial institutions or entities from time to time party thereto and Hercules Capital, Inc"
01/10/2023 8-K Other Events  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
12/23/2022 8-K Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulat...
Docs: "Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock",
"Legal Opinion of Hogan Lovells US LLP",
"Securities Purchase Agreement, by and among Madrigal Pharmaceuticals, Inc. and the institutional investors listed on the signature pages thereto",
"Amendment No. 2, to Securities Purchase Agreement, by and among Madrigal Pharmaceuticals, Inc. and the investors listed on the signature pages thereto",
"Madrigal Pharmaceuticals Announces $300+ Million in Financing Events to Advance Resmetirom Program"
12/19/2022 8-K Quarterly results
11/03/2022 8-K Quarterly results
08/04/2022 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Madrigal Pharmaceuticals Provides Clinical and Business Updates and Reports 2022 Second Quarter Financial Results"
06/17/2022 8-K Quarterly results
05/09/2022 8-K Quarterly results
05/09/2022 8-K Quarterly results
02/24/2022 8-K Quarterly results
11/04/2021 8-K Quarterly results
Docs: "Madrigal Pharmaceuticals Provides Corporate Update and Reports 2021 Third Quarter Financial Results"
08/05/2021 8-K Quarterly results
06/21/2021 8-K Quarterly results
06/01/2021 8-K Quarterly results
05/18/2021 8-K Quarterly results
05/06/2021 8-K Quarterly results
02/25/2021 8-K Quarterly results
11/05/2020 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Sales Agreement, by and between Madrigal Pharmaceuticals, Inc. and Cowen and Company, LLC",
"Legal Opinion of Hogan Lovells US LLP"
11/05/2020 8-K Quarterly results
Docs: "Madrigal Pharmaceuticals Announces Completion of Enrollment in Phase 3 MAESTRO NAFLD-1 Trial and Reports 2020 Third Quarter Financial Results and Highlights"
08/06/2020 8-K Quarterly results
06/18/2020 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/07/2020 8-K Quarterly results
02/26/2020 8-K Quarterly results
12/12/2019 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Underwriting Agreement, by and among Madrigal Pharmaceuticals, Inc., the Selling Stockholders, and Goldman Sachs & Co. LLC",
"Opinion of Hogan Lovells US LLP"
12/10/2019 8-K Quarterly results
11/06/2019 8-K Quarterly results
08/07/2019 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Madrigal Pharmaceuticals Reports 2019 Second Quarter Financial Results and Highlights"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy